{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:34:52Z","timestamp":1762868092344,"version":"3.37.3"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T00:00:00Z","timestamp":1586563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Micron Research Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We report the in vitro activity of ceftazidime\/avibactam and comparators against 7729 Enterobacterales isolates and 2053 Pseudomonas aeruginosa isolates collected from six Latin American countries between 2015 and 2017.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A central reference laboratory performed antimicrobial susceptibility testing using broth microdilution panels according to CLSI guidelines. The presence of \u03b2-lactamases was confirmed using multiplex PCR assays.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Susceptibility rates among Enterobacterales were highest for ceftazidime\/avibactam (99.3%, MIC90\u2009=\u20090.5\u2009mg\/L), meropenem (95.4%, MIC90\u2009=\u20090.12\u2009mg\/L) and amikacin (93.5%, MIC90\u2009=\u20098\u2009mg\/L). High susceptibility rates were observed for ceftazidime\/avibactam in all six countries. The majority of carbapenemase-positive isolates among Enterobacterales (N\u2009=\u2009366, 4.7%) were susceptible to ceftazidime\/avibactam (86.9%), colistin (76.8%) and amikacin (60.9%); MBL-positive isolates (N\u2009=\u200949, 0.6%) were susceptible only to colistin (79.6%), with a minority susceptible to amikacin (49.0%), aztreonam and levofloxacin (both 30.6%). Highest rates of susceptibility among P. aeruginosa isolates were for colistin (99.2%) and ceftazidime\/avibactam (86.6%), with rates of susceptibility to all other agents being &amp;lt;80.0%. MDR P. aeruginosa isolates (N\u2009=\u2009712, 34.7%) had a high rate of susceptibility to colistin (98.9%); the rate of susceptibility to ceftazidime\/avibactam was 61.4% and &amp;lt;50.0% to all other comparator agents. A total of 235 (11.4%) isolates of P. aeruginosa were carbapenemase positive and 148 (7.2%) were MBL positive; both subsets had high rates of susceptibility to colistin (98.3% and 100%, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ceftazidime\/avibactam susceptibility rates in Latin American countries are stable and high; ceftazidime\/avibactam can be an appropriate treatment for patients with infections caused by Enterobacterales or P. aeruginosa and for whom treatment options may be limited.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa089","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T19:14:16Z","timestamp":1585595656000},"page":"1859-1873","source":"Crossref","is-referenced-by-count":15,"title":["In vitro activity of ceftazidime\/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017"],"prefix":"10.1093","volume":"75","author":[{"given":"Gregory G","family":"Stone","sequence":"first","affiliation":[{"name":"Pfizer Essential Health, Groton, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Ponce-de-Leon","sequence":"first","affiliation":[{"name":"Clinical Microbiology Laboratory, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,11]]},"reference":[{"key":"2020061904541209700_dkaa089-B1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.diagmicrobio.2012.11.009","article-title":"Carbapenemase-resistant Enterobacteriaceae: a review of treatment and outcomes","volume":"75","author":"van Duin","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020061904541209700_dkaa089-B2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12879-017-2383-z","article-title":"Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary infection, pneumonia and sepsis","volume":"17","author":"Zilderberg","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2020061904541209700_dkaa089-B3"},{"year":"2019","key":"2020061904541209700_dkaa089-B4"},{"key":"2020061904541209700_dkaa089-B5","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1086\/432803","article-title":"Overview of nosocomial infections caused by Gram-negative bacilli","volume":"41","author":"Gaynes","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020061904541209700_dkaa089-B6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fcimb.2017.00039","article-title":"Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence","volume":"7","author":"Moradali","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"2020061904541209700_dkaa089-B7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-015-0926-5","article-title":"An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance","volume":"19","author":"Micek","year":"2015","journal-title":"Crit Care"},{"key":"2020061904541209700_dkaa089-B8","doi-asserted-by":"crossref","first-page":"e01076","DOI":"10.1128\/AAC.01076-18","article-title":"Past and present perspectives on \u03b2-lactamases","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061904541209700_dkaa089-B9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3389\/fmicb.2016.00895","article-title":"Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods","volume":"7","author":"Lee","year":"2016","journal-title":"Front Microbiol"},{"key":"2020061904541209700_dkaa089-B10","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00257-10","article-title":"Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to \u03b2-lactam antibiotics","volume":"54","author":"Alvarez-Ortega","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061904541209700_dkaa089-B11","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"2020061904541209700_dkaa089-B12","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1128\/AAC.00574-09","article-title":"Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa","volume":"53","author":"Rodriguez-Martinez","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061904541209700_dkaa089-B13","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1128\/AAC.01388-12","article-title":"Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones","volume":"56","author":"Cabot","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061904541209700_dkaa089-B14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of \u03b2-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061904541209700_dkaa089-B15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","article-title":"Diazabicyclooctanes (DBOs): a potent new class of non-\u03b2-lactam \u03b2-lactamase inhibitors","volume":"14","author":"Coleman","year":"2011","journal-title":"Curr Opin Microbiol"},{"key":"2020061904541209700_dkaa089-B16","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020061904541209700_dkaa089-B17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diagmicrobio.2015.02.003","article-title":"Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single \u03b2-lactamases","volume":"82","author":"Papp-Wallace","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020061904541209700_dkaa089-B18","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1128\/AAC.04218-14","article-title":"In vitro antibacterial activity of the ceftazidime-avibactam combination against Enterobacteriaceae, including strains with well-characterized \u03b2-lactamases","volume":"59","author":"Levasseur","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061904541209700_dkaa089-B19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dkp197","article-title":"In vitro activity of the \u03b2-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases","volume":"64","author":"Stachyra","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2020061904541209700_dkaa089-B20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","article-title":"Interplay between \u03b2-lactamases and new \u03b2-lactamase inhibitors","volume":"17","author":"Bush","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"2020061904541209700_dkaa089-B21","doi-asserted-by":"crossref","first-page":"e00592","DOI":"10.1128\/AAC.00592-18","article-title":"In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program from 2012 to 2015","volume":"62","author":"Kazmierczak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061904541209700_dkaa089-B22","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/AAC.04191-14","article-title":"In vitro susceptibility of characterized \u03b2-lactamase-producing strains tested with avibactam combinations","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061904541209700_dkaa089-B23","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"year":"2019","key":"2020061904541209700_dkaa089-B24"},{"key":"2020061904541209700_dkaa089-B25","doi-asserted-by":"crossref","first-page":"e01814","DOI":"10.1128\/AAC.01814-18","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Latin American countries: results from the INFORM global surveillance program, 2012\u20132015","volume":"63","author":"Karlowsky","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"year":"2015","key":"2020061904541209700_dkaa089-B26"},{"year":"2019","key":"2020061904541209700_dkaa089-B27"},{"key":"2020061904541209700_dkaa089-B28","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"year":"2019","key":"2020061904541209700_dkaa089-B29"},{"key":"2020061904541209700_dkaa089-B30","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART Program, 2009 to 2013","volume":"59","author":"Lob","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061904541209700_dkaa089-B31","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1128\/AAC.00220-16","article-title":"In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014)","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061904541209700_dkaa089-B32","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.bjid.2017.03.008","article-title":"The in vitro activity of ceftazidime-avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in S\u00e3o Paulo, Brazil","volume":"21","author":"Rossi","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"2020061904541209700_dkaa089-B33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bjid.2017.03.006","article-title":"Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries","volume":"21","author":"Karlowsky","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"2020061904541209700_dkaa089-B34","doi-asserted-by":"crossref","first-page":"e0198621","DOI":"10.1371\/journal.pone.0198621","article-title":"Antimicrobial susceptibility of gram-negative bacilli isolated from intra-abdominal and urinary-tract infections in Mexico from 2009 to 2015: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)","volume":"13","author":"Ponce-de-Leon","year":"2018","journal-title":"PLoS One"},{"key":"2020061904541209700_dkaa089-B35","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/ofid\/ofy343","article-title":"Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 years from the SENTRY antimicrobial surveillance program, 1997\u20132016","volume":"6 Suppl 1","author":"Shortridge","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2020061904541209700_dkaa089-B36","doi-asserted-by":"crossref","first-page":"e0209865","DOI":"10.1371\/journal.pone.0209865","article-title":"A snapshot of antimicrobial resistance in Mexico. Results from 47 centers from 20 states during a six-month period","volume":"14","author":"Garza-Gonz\u00e1lez","year":"2019","journal-title":"PLoS One"},{"key":"2020061904541209700_dkaa089-B37","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"van Duin","year":"2017","journal-title":"Virulence"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/7\/1859\/33405091\/dkaa089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/7\/1859\/33405091\/dkaa089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T08:55:30Z","timestamp":1592556930000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/7\/1859\/5819166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,11]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,4,11]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa089","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,4,11]]}}}